THEO-260
AXP000056.1 · Oncolytic virus
- Platform
- adenovirus
- Originator
- Theolytics
- Sponsor
- Theolytics
Names
| Name | Type | Source |
|---|---|---|
| THEO-260 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus (serotype not reported)
- Modifications
- selected by directed evolution; replicates in cancer cells and cancer-associated fibroblasts
- Route
- intraperitoneal
- Source
- evidence
Cross-references
- NCI Thesaurus
- C222794
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07211659 | Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients | Recruiting | Phase 1 | 2026-02-13 | 2027-09 | 18 | Ovarian Cancer |
| NCT06618235 | Trial of THEO-260 in Ovarian Cancer Patients | Recruiting | Phase 1/2 | 2024-09-24 | 2028-06 | 44 | Ovarian Cancer |
Recent changes
No changes recorded in its trials yet.
Notes
Selected by directed evolution; replicates in cancer cells and in cancer-associated fibroblasts. First patient dosed November 2024 in the phase 1/2a OCTOPOD trial in ovarian cancer (intraperitoneal). Backbone serotype not stated in sources consulted.
How to cite
THEO-260 (AXP000056.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000056.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.